Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Denosumab biosimilar - Biocon Biologics

Next Previous
Drug Profile

Denosumab biosimilar - Biocon Biologics

Alternative Names: Aukelso; Bmab-1000; Bosaya; denosumab-kyqq; Evfraxy; Vevzuo

Latest Information Update: 28 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biocon Biologic
  • Developer Biocon; Biocon Biologic
  • Class Antihypercalcaemics; Antineoplastics; Antirheumatics; Calcium regulators; Immunotherapies; Monoclonal antibodies; Osteoporosis therapies
  • Mechanism of Action RANK ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Bone disorders; Corticosteroid-induced osteoporosis; Giant cell tumour of bone; Osteoporosis; Postmenopausal osteoporosis
  • Registered Giant cell tumours

Most Recent Events

  • 28 Oct 2025 No recent reports of development identified for phase-I development in Osteoporosis(In volunteers) in USA (SC, Injection)
  • 09 Oct 2025 Launched for Corticosteroid-induced osteoporosis in USA (SC)
  • 01 Oct 2025 Biocon Biologics and Amgen executes the settlement and license agreement to resolve the pending patent litigation about the denosumab biosimilar

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top